Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CEP-11981 by Teva Pharmaceutical Industries for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Data Insights
CEP-11981 by Teva Pharmaceutical Industries for Adenocarcinoma: Likelihood of Approval
CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Adenocarcinoma. According to GlobalData, Phase...